Skip to main content

Invivyd (NASDAQ: IVVD) — Company Overview, News & Financial Data

Invivyd logo
IVVD Invivyd
Invivyd primary media
Company profile

Invivyd

Invivyd (NASDAQ:IVVD) is a biotechnology company focused on developing innovative solutions to combat infectious diseases, with a particular emphasis on antibodies designed to prevent and treat various viral infections. Their operations span from early-stage research to advanced clinical trials, aiming to address the unmet medical needs in the infectious disease space. Invivyd's projects include developing therapies that could provide immediate and long-term immunity against challenging viruses, leveraging cutting-edge technology and scientific research. The company's objectives are centered around delivering high-impact solutions to global health threats, fostering partnerships with leading health organizations, and ultimately, improving patient outcomes through the power of immunology and biotechnology innovations.

Snapshot

Public USOwnership
2020Year founded
101Employees
Waltham, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Waltham, US

Products and/or services of Invivyd

  • Development of antibody therapeutics targeting infectious diseases.
  • Advancements in the prevention and treatment of HIV.
  • Research on monoclonal antibodies for COVID-19 prophylaxis and treatment.
  • Pipeline of products aimed at combating respiratory syncytial virus (RSV).
  • Innovations in biotechnology to enhance drug delivery mechanisms.
  • Collaboration on global health initiatives for vaccine-preventable diseases.

Invivyd executive team

  • Marc William EliaCEO & Chairperson of the Board
  • William E. Duke Jr.CFO and Principal Financial & Accounting Officer
  • Jill AndersenChief Legal Officer & Corporate Secretary
  • Timothy LeeChief Commercial Officer
  • Robert D. AllenChief Scientific Officer
  • Kristie Coneys KuhlChief Communications Officer
  • Julie GreenChief Human Resources Officer
  • Rachael GerlachSenior Vice President of Regulatory Affairs
  • Katie FalzoneSenior Vice President of Finance
  • Michael J. MinaChief Medical Officer & Chief Epidemiologist